Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma

Journal of Chemotherapy

Volumn 22, Issue 3, 2010, Pages 186-190

  Fujita, Y ^a   Nakamura, T ^a,b   Aomori, T ^a,b   Nishiba, H ^a   Shinozaki, T ^b   Yanagawa, T ^b   Takagishi, K ^d   Watanabe, H ^c   Okada, Y ^b   Nakamura, K ^b   Horiuchi, R ^a,b   Yamamoto, Koujirou ^a,b  

^a GUNMA UNIVERSITY HOSPITAL   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d NONE

Author keywords

5 Year survival rate; Methotrexate; Osteosarcoma; Pharmacokinetic individualization

Indexed keywords

BLEOMYCIN; CISPLATIN; DACTINOMYCIN; IFOSFAMIDE; METHOTREXATE; PIRARUBICIN; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OSTEOSARCOMA; OUTCOME ASSESSMENT; SCHOOL CHILD; SURVIVAL RATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

EID: 78650239053     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.3.186     Document Type: Article

References (17)

1. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297 (12): 630-634. (Pubitemid 8200049)
2. Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995; 15 (2): 489-494.
3. Delepine N, Delepine G, Bacci G, Rosen G, Desbois JC. Influence of methotrexate dose intensity on outcome of patients with high-grade osteogenic osteosarcoma. Analysis of the literature. Cancer 1996; 78 (10): 2127-2135. (Pubitemid 26367605)
4. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12 (7): 1443-1451.
5. Bacci G, Picci P, Ferrari S, Sangiorgi L, Mercuri M, Bertoni F, et al. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results. Chir. Organi Mov 1995; 80 (1): 1-10.
6. Bacci G, Ferrari S, Picci P, Zolezzi C, Gherlinzoni F, Iantomo D, et al. Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs. J Chemother 1996; 8 (6): 472-478. (Pubitemid 27022552)
7. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998; 16(2): 658-663. (Pubitemid 28135613)
8. Kwong DL, Ha SY, Chau KY, Choi PH, Chan GC, Kwong PW, et al. Multidisciplinary management of osteosarcoma: Experience in Hong Kong. Pediatr Hematol Oncol 1998; 15 (3): 229-236. (Pubitemid 28261826)
9. Zelcer S, Kellick M, Wexler LH, Shi W, Sankaran M, Lo S, et al. Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005; 44 (7): 638-642.
10. Pinedo HM, Chabner RA. Role of drug concentration, duration of exposure and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treat Rep 1977; 61 (4): 709-715. (Pubitemid 8156485)
11. Shinozaki T, Watanabe H, Yanagawa T, Shirakura K, Takagishi K. Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother. 2002; 36 (6): 996-999. (Pubitemid 34564382)
12. Yamaoka K, Tanigawara K, Nakagawa T, Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodyn. 1981; 4 (11): 879-885. (Pubitemid 12174128)
13. Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, et al. High dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004; 100 (8): 1724-1733. (Pubitemid 38456352)
14. Ferrari S, Sassoli V, Orlandi M, Strazzari S, Puggioli C, Battistini A, et al. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 1993; 5 (2): 135-141. (Pubitemid 23174132)
15. Miyauchi Y, Mii Y, Morishita T, Miura S, Honoki K, Aoki M, et al. A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy. Gan To Kagaku Ryoho 1996; 23 (5): 595-599. (Pubitemid 26152381)
16. Gaffney R, Unni KK, Sim FH, Slezak JM, Esther RJ, Bolander ME. Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era. Hum Pathol 2006; 37 (8): 1009-1014. (Pubitemid 44080805)
17. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32 (6): 423-436. (Pubitemid 44309249)